Athira pharma presents new clinical and preclinical data at the american academy of neurology (aan) 2023 annual meeting

Fosgonimeton improves mmse (mini-mental state evaluation) after six months in a post hoc analysis from the phase 2 act-ad trial in mild-to-moderate alzheimer's disease
ATHA Ratings Summary
ATHA Quant Ranking